Case Reports in Oncology最新文献

{"title":"Erratum.","authors":"","doi":"10.1159/000551297","DOIUrl":"https://doi.org/10.1159/000551297","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000547815.].</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"458"},"PeriodicalIF":0.7,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13061403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147644016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Case of Complete Remission in Metastatic Esophageal Squamous Cell Carcinoma: Potential Abscopal Effect of Combined Immunotherapy and Radiotherapy - A Case Report.","authors":"Ingrid Zuniga Ott, Guacimara Ortega Sanchez","doi":"10.1159/000550793","DOIUrl":"https://doi.org/10.1159/000550793","url":null,"abstract":"<p><strong>Introduction: </strong>Esophageal squamous cell carcinoma (SCC) is an aggressive malignancy associated with a poor prognosis, even when managed with multimodal therapeutic approaches.</p><p><strong>Case presentation: </strong>This case report describes a 38-year-old woman who developed metastatic esophageal SCC following prior optimal treatment for initially locoregional disease. Due to poor tolerance of neoadjuvant chemotherapy and programmed death-ligand 1 (PD-L1)/tumor proportion score (TPS) of 5%, palliative immunotherapy with ipilimumab and nivolumab was initiated. After nodal progression during dual immunotherapy, the addition of palliative local radiotherapy to an inguinal lymph node, delivering a total dose of 20 Gray (Gy)/25 Gy/35 Gy over 5 fractions, resulted in complete remission of the thoraco-abdominal metastases. Fifteen months after the administration of palliative radiotherapy, an oligopersistent cervical lymph node was treated with stereotactic radiotherapy (5 × 5 Gy/7 Gy = 25 Gy/35 Gy). More than 2 years following the diagnosis of metastatic disease, the patient remains without evidence of disease.</p><p><strong>Conclusion: </strong>This case demonstrates an excellent response to combined immunotherapy in advanced esophageal SCC, including a rare abscopal effect following short-course radiotherapy.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"471-481"},"PeriodicalIF":0.7,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13065308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Importance of Cerebrospinal Fluid Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia.","authors":"Tülin Tiraje Celkan, Zafer Başlar, Rejin Kebudi, Hale Ören","doi":"10.1159/000551123","DOIUrl":"https://doi.org/10.1159/000551123","url":null,"abstract":"<p><strong>Introduction: </strong>Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Central nervous system (CNS) leukemia is usually diagnosed using microscopy and cytospin-based cytology, which has low sensitivity for detecting minimal events. Following the evaluation of bone marrow aspiration samples using flow cytometry (FC), it has been found to be valuable in the risk group stratification and follow-up of ALL. Recently, there have been discussions regarding the routine use of cerebrospinal fluid (CSF) FC analysis for CNS leukemia at diagnosis and/or relapse in ALL protocols.</p><p><strong>Case presentation: </strong>We present a case of ALL in which the CSF cytospin-based cytology analysis revealed no blasts, whereas the FC analysis of the CSF showed 1.6% blasts during the maintenance therapy. The patient developed an overt CNS relapse within 3 months.</p><p><strong>Conclusion: </strong>We would like to emphasize the importance of using more sensitive techniques to evaluate CNS involvement in patients with ALL.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"508-513"},"PeriodicalIF":0.7,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13108952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Almonertinib-Induced Interstitial Lung Disease in an NSCLC Patient Harboring an EGFR Ex19del Mutation: A Case Report.","authors":"Xi Gao, Dongmei He, Hang Yang, Xuezhou Pang, Lan Liang","doi":"10.1159/000550877","DOIUrl":"https://doi.org/10.1159/000550877","url":null,"abstract":"<p><strong>Introduction: </strong>Almonertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor, has demonstrated favorable clinical efficacy in the treatment of non-small cell lung cancer and is recommended as a first-line treatment for patients with EGFR-sensitive mutations. Although it rarely induces interstitial lung disease (ILD), we report a case of a stage IVB EGFR Ex19del mutation in an older female adult with almonertinib-induced grade 3 ILD.</p><p><strong>Case presentation: </strong>A 55-year-old Asian woman diagnosed with stage IVB lung adenocarcinoma (cT4N3M1c per the AJCC 8th edition) presented with extensive metastases involving the right hilar, mediastinal, bilateral cervical, retroperitoneal lymph nodes, bilateral adrenal glands, brain, and bone. Following the detection of an EGFR Ex19del mutation, she was initiated on almonertinib treatment. Notably, progressive respiratory deterioration developed 3 months post-treatment, characterized by dyspnea, hypoxemia, and interstitial lung changes on high-resolution computed tomography. ILD diagnosis was confirmed through multidisciplinary consensus. Immediate discontinuation of almonertinib combined with intravenous methylprednisolone resulted in significant clinical and radiological improvement within 7 days.</p><p><strong>Conclusion: </strong>This case highlights two important clinical implications: (1) almonertinib-associated ILD can rapidly progress to a life-threatening condition and (2) occupational inhalational exposures (e.g., dust and smoking) have been directly and indirectly implicated as potential risk factors for EGFR-TKI-induced pulmonary toxicity in prior studies and may have contributed to the outcome in this case. Clinicians should maintain heightened vigilance for respiratory complications during almonertinib therapy, particularly in patients with preexisting pulmonary risk factors.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"490-498"},"PeriodicalIF":0.7,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marked Leukocytosis and Subclavian Vein Occlusion from Pancoast Tumor Mimicking Cellulitis: A Case Report.","authors":"Hiroshi Shintani, Naoki Kataoka","doi":"10.1159/000551217","DOIUrl":"https://doi.org/10.1159/000551217","url":null,"abstract":"<p><strong>Introduction: </strong>Lung cancer can present with atypical clinical manifestations that may mimic benign conditions. We report an extremely rare case of lung cancer initially misdiagnosed as cellulitis due to unilateral upper limb swelling and elevated inflammatory markers.</p><p><strong>Case presentation: </strong>A 65-year-old woman with a history of heavy smoking presented with progressive swelling and pain in the left upper limb, accompanied by leukocytosis and elevated inflammatory markers. She was initially diagnosed with cellulitis and treated with antibiotics without improvement. Contrast-enhanced computed tomography revealed a left apical lung tumor invading the chest wall and occluding the subclavian vein. Histopathological examination confirmed primary non-small-cell lung carcinoma, favoring adenocarcinoma. The patient also exhibited tumor-associated extreme leukocytosis and experienced rapid disease progression despite supportive care, dying 37 days after admission.</p><p><strong>Discussion: </strong>This case illustrates the diagnostic challenges posed by lung cancer presenting with atypical, infection-like manifestations. Pancoast tumors involving the subclavian vein can cause upper limb edema, while tumor-associated leukocytosis can mimic inflammatory responses. Because extreme leukocytosis in solid tumors is associated with poor prognosis, early recognition is crucial.</p><p><strong>Conclusion: </strong>Even when clinical findings suggest infection, malignancy should be considered in the differential diagnosis, particularly in patients with risk factors such as smoking or advanced age. Prompt chest imaging is essential to avoid diagnostic delay in such cases.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"482-489"},"PeriodicalIF":0.7,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13075874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147688532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Merkel Cell Carcinoma Involving the Cerebrospinal Fluid: A Case Report.","authors":"Cade A Cantu, Asthra A Palla, Amruth P Ratnakar","doi":"10.1159/000551098","DOIUrl":"https://doi.org/10.1159/000551098","url":null,"abstract":"<p><strong>Introduction: </strong>Merkel cell carcinoma (MCC) is a rare skin cancer with very low incidence, so community oncologists do not encounter many cases of this pathology in their day-to-day practice. Central nervous system (CNS) involvement by MCC is an extremely rare manifestation of this already rare pathology, and so not many cases are available in the literature.</p><p><strong>Case presentation: </strong>We present a case of an 83-year-old woman that was seen at our facility with MCC involving the cerebrospinal fluid (CSF).</p><p><strong>Conclusion: </strong>There are no specific guidelines for treatment of MCC involving the CNS, so description of every single case of MCC involving CNS is of utmost importance so as to (a) help increase awareness of this entity among clinicians, (b) highlight different treatment approaches being implemented at different facilities, and (c) eventually help develop best treatment guidelines to treat such cases.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"450-457"},"PeriodicalIF":0.7,"publicationDate":"2026-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13056348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative Oncology Approach in Advanced Myxofibrosarcoma: A Case Report of Prolonged Survival with High-Dose Vitamin C and <i>Viscum album</i>.","authors":"David Gigineishvili, Tamar Rukhadze, Maurice Orange","doi":"10.1159/000550177","DOIUrl":"https://doi.org/10.1159/000550177","url":null,"abstract":"<p><strong>Introduction: </strong>Myxofibrosarcoma (MFS) is a rare and aggressive soft tissue sarcoma with high recurrence and metastasis rates. The prognosis in advanced metastatic disease is poor, with median survival time ranging from 12 to 24 months despite multimodal therapy. Integrative oncology approaches, such as high-dose vitamin C and <i>Viscum album</i>, are increasingly explored as adjuncts in both curative and palliative cancer care.</p><p><strong>Case presentation: </strong>We present the case of a 59-year-old male with high-grade unresectable MFS of the right buttock and spinal metastases. Standard palliative treatments (systemic chemo- and radiotherapy, followed by targeted and immunotherapy) were combined with high-dose intravenous vitamin C and <i>V. album</i> extracts given intravenously, subcutaneously, and intratumorally. Despite the progression of the disease and COVID-19 comorbidity, the patient survived for 48 months, exceeding conventional survival estimates.</p><p><strong>Conclusion: </strong>This case suggests that integrative oncology combining systemic anticancer therapy with high-dose vitamin C and <i>V. album</i> extracts may enhance tolerance and extend survival in advanced MFS. Further prospective studies are warranted to corroborate the value of complementary therapy in sarcoma management.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"459-470"},"PeriodicalIF":0.7,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13061405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147644025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Myeloid Leukemia Transforming into Acute Lymphoblastic Leukemia in a Patient with Gaucher Disease: A Case Report and Literature Review.","authors":"Başak Sayınalp Arslan, Fatma Tuğba Çatan Erdekli, Arzu Sağlam Ayhan, Elifcan Aladağ Karakulak, Ümit Yavuz Malkan, Yahya Büyükaşık","doi":"10.1159/000550944","DOIUrl":"10.1159/000550944","url":null,"abstract":"<p><strong>Introduction: </strong>Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder characterized by glucocerebrosidase deficiency and accumulation of glucosylceramide within macrophages. Although GD is associated with an increased risk of hematologic malignancies - particularly multiple myeloma - the coexistence of GD with chronic myeloid leukemia (CML) is exceedingly rare. Even more unusual is leukemic transformation of CML into acute lymphoblastic leukemia (ALL) in the setting of GD, a phenomenon not previously documented in the literature. Understanding such associations is essential as chronic inflammation, altered macrophage biology, and immune dysregulation in GD may influence oncogenesis and disease evolution.</p><p><strong>Case presentation: </strong>We report a 54-year-old man with GD type 1, splenectomized in childhood and on long-term enzyme replacement therapy, who was diagnosed with Philadelphia chromosome-positive CML following evaluation for leukocytosis. Despite an initial optimal response to imatinib, his molecular response plateaued, and 1 year later he developed relapse with B-lymphoblastic transformation. Flow cytometry and molecular studies confirmed B-ALL. The patient was treated with the EWALL protocol combined with dasatinib, achieving complete remission and MRD negativity. During consolidation, he developed severe neutropenic fever, fungal pneumonia, and massive pleural effusion attributed to dasatinib. Therapy was switched to bosutinib with successful control of effusion and sustained molecular remission for 27 months.</p><p><strong>Conclusion: </strong>This is the first reported case of B-ALL transformation arising from CML in a patient with underlying GD. The case highlights that malignancies in the context of GD may follow an accelerated or atypical course. Close monitoring for disease evolution and careful management of TKI-related toxicities are critical in this unique clinical setting.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"437-443"},"PeriodicalIF":0.7,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13030901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment with Daratumumab in Combination with Glucocorticosteroids as First-Line Treatment Achieves a Complete Remission for a Patient with Multiple Myeloma and Resolves Neutropenia: A Case Report.","authors":"Sarah Mettias, Jamie Cheung, Jonathan Moore, James R Berenson","doi":"10.1159/000549657","DOIUrl":"10.1159/000549657","url":null,"abstract":"<p><strong>Introduction: </strong>Multiple myeloma (MM) is a bone marrow malignancy of plasma cells that can be treated with monoclonal antibodies (mAbs) including daratumumab. This mAb binds to CD38 proteins expressed on MM cells, allowing the immune system to recognize and kill these tumor cells. Neutropenia is a common complication in MM, often attributed to the disease itself or treatment with agents such as immunomodulatory drugs. However, its resolution with first-line mAb therapy has not previously been reported.</p><p><strong>Case presentation: </strong>We report a case of a 32-year-old Filipino female with smoldering MM. She developed neutropenia and as a result was treated with a combination of daratumumab and glucocorticosteroids. She achieved a complete remission (CR), and her absolute neutrophil count normalized. The treatment was well tolerated with no adverse effects reported, and the patient remains in CR after more than 3 years of therapy.</p><p><strong>Discussion: </strong>This case highlights the potential for daratumumab combined with glucocorticosteroids alone to effectively manage a patient's MM and severe neutropenia, suggesting a dual therapeutic benefit without treatment-related toxicity. Our findings support the consideration of daratumumab and glucocorticosteroids as a viable first-line therapeutic option for patients with MM who develop neutropenia.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"410-416"},"PeriodicalIF":0.7,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kaposi's Sarcoma in a Kidney Transplant Recipient: A Case Report on Paclitaxel Response.","authors":"Hiba Ghabi, Marwa Trabelsi, Alia Zheni, Syrine Tlili, Lamia Rais, Fethi Ben Hmida, Ikram Mami, Mouhamed Karim Zouaghi","doi":"10.1159/000547250","DOIUrl":"10.1159/000547250","url":null,"abstract":"<p><strong>Introduction: </strong>In immunocompromised individuals, particularly organ transplant recipients, the risk of developing Kaposi sarcoma (KS) increases significantly due to prolonged immunosuppressive therapy. The onset of post-transplant KS is highly variable, though most cases occur within the first 2 years following transplantation. The effectiveness and safety of systemic therapies, in the management of post-transplant KS are not well established. In this report, we describe a rare case of early-onset KS in a Tunisian kidney transplant recipient, revealed by deep vein thrombosis just 6 months after transplantation and successfully managed with paclitaxel as first-line therapy.</p><p><strong>Case presentation: </strong>We present the case of a 52-year-old Tunisian male who underwent a living-donor kidney transplant in June 2022. Six months after transplantation, the patient presented with deep vein thrombosis and large purplish plaques were observed on the anterior left thigh. A skin biopsy confirmed the diagnosis of KS. Further Investigations revealed systemic involvement. The patient was treated with paclitaxel-based chemotherapy in combination with sirolimus and a reduction in immunosuppressive therapy. As of November 2024, the patient had demonstrated marked clinical improvement, with resolution of KS lesions and stable renal function.</p><p><strong>Conclusion: </strong>This case of early-onset KS highlights the potential effectiveness of paclitaxel-based chemotherapy combined with sirolimus and a carefully adjusted reduction in immunosuppressive therapy as a promising first-line treatment option.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"334-341"},"PeriodicalIF":0.7,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12965734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147375985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}